Sign In
Buy CAPR
$25.33
-0.680 (-2.61%)
At Close: Jun 10, 2026
Capricor Therapeutics Announces Development of Serology Test to Confirm Activity of SARS-CoV-2 Vaccines
09:15am, Monday, 01'st Feb 2021
-Technology Licensed from Johns Hopkins University-
Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes
09:15am, Tuesday, 19'th Jan 2021
-Enhanced Signaling Pathways Show Increased Potency Through Expression of MicroRNAs-
—Capricor to leverage Lonza's expertise in technology transfer and development of cellular therapies to take CAP-1002 through potential product launch and commercial supply—
Capricor Therapeutics Announces DSMB Recommendation to Continue Phase II INSPIRE Trial for Severe COVID-19 Patients
09:15am, Tuesday, 29'th Dec 2020
Trial Assessing Ability of Capricor's Cardiac Cell Therapy, CAP-1002, to Reduce the Cytokine Storm Associated with Severe COVID-19 Trial Assessing Ability of Capricor's Cardiac Cell Therapy, CAP-1002,
Capricor Therapeutics, Inc's (CAPR) CEO Linda Marbán on Q3 2020 Results - Earnings Call Transcript
10:43pm, Thursday, 12'th Nov 2020
Capricor Therapeutics, Inc's (CAPR) CEO Linda Marbán on Q3 2020 Results - Earnings Call Transcript
Capricor Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
04:01pm, Thursday, 12'th Nov 2020
Exosome Platform Technology -Announced Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19- - Novel Vaccine Induce d Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins - -De
Capricor Therapeutics Announces Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19
09:15am, Monday, 09'th Nov 2020
Potential Vaccine Candidate Employs Novel Exosome-Based mRNA Delivery Platform that Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins
Capricor Therapeutics to Present Third Quarter 2020 Financial Results and Recent Corporate Update on November 12
09:00am, Thursday, 05'th Nov 2020
Company to Host Conference Call and Webcast, November 12, 2020, at 4:30 p.m. ET Company to Host Conference Call and Webcast, November 12, 2020, at 4:30 p.m. ET
Capricor Therapeutics (CAPR) Investor Presentation - Slideshow
02:40pm, Tuesday, 08'th Sep 2020
The following slide deck was published by Capricor Therapeutics, Inc. in conjunction with this event..
Capricor Therapeutics (NASDAQ:CAPR) Coverage Initiated by Analysts at Maxim Group
01:46am, Tuesday, 11'th Aug 2020
Research analysts at Maxim Group initiated coverage on shares of Capricor Therapeutics (NASDAQ:CAPR) in a research report issued to clients and investors on Friday, AnalystRatings.com reports. The bro
The Daily Biotech Pulse: Novavax Vaccine Deals, Trevena Awaits FDA Decision, 2 IPOs
12:00am, Friday, 07'th Aug 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 6)
ADiTx Therapeutics Inc (NASDAQ: ADTX) (announced introduction of AditxtScore for COVID-19 to be used in detecting...
Capricor Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
08:01pm, Thursday, 06'th Aug 2020
Exosome Platform for COVID-19 -Novel Multivalent Exosome mRNA and VLP Vaccine Candidates Underway in Animal Studies- -Preclinical Data Shows Positive Antibody Response-CAP-1002 for COVID-19 -Expand
Capricor Therapeutics to Present Second Quarter 2020 Financial Results and Recent Corporate Update on August 6
01:15pm, Thursday, 30'th Jul 2020
Company to Host Conference Call and Webcast, August 6, 2020, at 4:30 p.m. ETLOS ANGELES, July 30, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company f
The Daily Biotech Pulse: Merck's Breakthrough Therapy Designation, Sonoma Surges On Sanitizer News, Sanofi-Glaxo And More
12:00am, Wednesday, 29'th Jul 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 28)
Axonics Modulation Technologies Inc (NASDAQ: AXNX)
Capricor Therapeutics Inc (NASDAQ: CAPR)
Fulgent Genetics Inc...
Capricor Therapeutics (CAPR) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
04:33pm, Tuesday, 28'th Jul 2020
Capricor (CAPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
